Granted Patent
B2
US 12,661,383 · App. 18/305,899 · Granted Jun 23, 2026
Proteins for the treatment of epithelial barrier function disorders
Inventors:
Andrew Wonhee Han (San Francisco, CA); Andrew Whitman Goodyear (Pacifica, CA); Tarunmeet Gujral (Foster City, CA); Todd Zachary DeSantis (Livermore, CA); Karim Dabbagh (Mountain View, CA); Toshihiko Takeuchi (Oakland, CA); Ye Jin (Danville, CA); Michi Izumi Willcoxon (Palo Alto, CA); Stefanie Banas (Concord, CA)
Assignee:
Genevive, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The disclosure relates to therapeutic proteins and pharmaceutical compositions comprising said proteins, which have utility in treating various human diseases. In particular aspects, the disclosed therapeutic proteins are useful for treating human gastrointestinal inflammatory diseases and gastrointestinal conditions associated with decreased epithelial cell barrier function or integrity. Further, the disclosed therapeutic proteins are useful for treating human inflammatory bowel disease, including inter alia, Crohn's disease and ulcerative colitis.
Claims (13)
1 . A synthetic protein, comprising: an amino acid sequence having at least 98% sequence identity to SEQ ID NO: 19, wherein the amino acid at position 147 is not cysteine and/or the amino acid at position 151 is not cysteine.
2 . The synthetic protein of claim 1 , wherein the amino acid at position 147 is valine.
3 . The synthetic protein of claim 1 , wherein the amino acid at position 151 is serine.
4 . The synthetic protein of claim 1 , wherein the amino acid at position 147 is valine, and the amino acid at position 151 is serine.
5 . The synthetic protein of claim 1 , wherein the amino acid at position 84 is aspartic acid.
6 . The synthetic protein of claim 1 , wherein the amino acid at position 84 is aspartic acid, and the amino acid at position 147 is valine, and the amino acid at position 151 is serine.
7 . The synthetic protein of claim 1 , wherein the amino acid at position 83 is serine.
8 . The synthetic protein of claim 1 , wherein the amino acid at position 83 is serine, and the amino acid at position 147 is valine, and the amino acid at position 151 is serine.
9 . The synthetic protein of claim 1 , wherein the amino acid at position 53 is serine.
10 . The synthetic protein of claim 1 , wherein the amino acid at position 53 is serine, and the amino acid at position 84 is aspartic acid, and the amino acid at position 147 is valine, and the amino acid at position 151 is serine.
11 . The synthetic protein of claim 1 , wherein the amino acid at position 53 is serine, and the amino acid at position 83 is serine, and the amino acid at position 147 is valine, and the amino acid at position 151 is serine.
12 . The synthetic protein of claim 1 , wherein the amino acid at position 83 is not asparagine and/or the amino acid at position 53 is not asparagine.
13 . A pharmaceutical composition, comprising: the synthetic protein of claim 1 and a pharmaceutically acceptable carrier.
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Feb 5, 2024
From: SECOND GENOME, INC.
To: GENEVIVE, INC.
Reel/Frame 066385/0362 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 23, 2023
From: HAN, ANDREW WONHEE; GOODYEAR, ANDREW WHITMAN; GUJRAL, TARUNMEET; DESANTIS, TODD ZACHARY; DABBAGH, KARIM; TAKEUCHI, TOSHIHIKO; JIN, YE; WILLCOXON, MICHI IZUMI; BANAS, STEFANIE
To: SECOND GENOME, INC.
Reel/Frame 063727/0616 →
Continuity (6)
Provisional Application
62611334
· Dec 28, 2017
Provisional Application
62607706
· Dec 19, 2017
Provisional Application
62482963
· Apr 7, 2017
References Cited (154)
US 4399216A
· Axel
· 1983
[cited by applicant]
US 5767063A
· Lee
· 1998
[cited by applicant]
US 20060189526A1
· Podolsky
· 2006
[cited by applicant]
US 20100144618A1
· Podolsky
· 2010
[cited by applicant]
CN 101184507A
· 2008
[cited by applicant]
WO WO2002078640A2
· 2002
[cited by applicant]
WO WO2013050792
· 2013
[cited by applicant]
WO WO2015014973
· 2015
[cited by applicant]
WO WO2016203221
· 2016
[cited by applicant]
WO WO2018187682
· 2018
[cited by applicant]
NCBI reference for WP_014079420.1 (downloaded from https://www.ncbi.nlm.nih.gov/protein/WP_014079420.1?report=genbank&log$=protalign&blast_rank=1&RID=XCKE8H21015; published May 18, 2013) (Year: 2013).
[cited by examiner]
G2T1E5 Uniprot (downloaded from https://www.uniprot.org/uniprot/G2T1E5; last modified Nov. 16, 2011) (Year: 2011).
[cited by examiner]
CN Office Action in Chinese Appln. No. 201880037987.0, mailed on May 31, 2024, 25 pages (with English translation).
[cited by applicant]
KR Office Action in Korean Appln. No. 10-2023-7032575, mailed on May 23, 2024, 13 pages (with English translation).
[cited by applicant]
Altschul et al., “Basic local alignment search tool”, J. Mol. Biol. 215: 403-410, 1990.
[cited by applicant]
Altschul et al., “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs”, Nucleic Acids Res. 25(17): 3389-3402, 1997.
[cited by applicant]
Antonsson et al., “Induction of apoptosis by staurosporine involves the inhibition of expression of the major cell cycle proteins at the G(2)/m checkpoint accompanied by alterations in Erk and Akt kinase activities.” An…
[cited by applicant]
Aroniadis et al. “Fecal microbiota transplantation: past, present and future.” Curr. Opin. Gastroenterol. 29 (1): 79-84, 2013.
[cited by applicant]
Ayoubi et al., “Regulation of gene expression by alternative promoters.”, FASEB J. 10, 453-60, 1996.
[cited by applicant]
Baron et al., “Variation Between Observers in Describing Mucosal Appearances in Proctocolitis”, BMJ, 1: 89, 1964.
[cited by applicant]
Beduneau et al., “A tunable Caco-2/HT29-MTX co-culture model mimicking variable permeabilities of the human intestine obtained by an original seeding procedure.” Eur J Pharm Biopharm., 87 (2): 290-298, 2014.
[cited by applicant]
Behrendt et al., “Lipopolysaccharide binding protein in preterm infants.”, Arch Dis Child Fetal Neonatal Ed 89: F551-554, 2004.
[cited by applicant]
Berge et al., “Pharmaceutical salts”, J. Pharm. Sci. 66: 1-19, 1977.
[cited by applicant]
Berger et al., “Oleic Acid Uptake Reveals the Rescued Enterocyte Phenotype of Colon Cancer Caco-2 by HT29-MTX Cells in Co-Culture Mode”, Int J Mol Sci, 18: 1573, 21 pages, 2017.
[cited by applicant]
Best et al., “Development of a Crohn's disease activity index.”, National Cooperative Crohn's Disease Study, Gastroenterol. 70: 439-444, 1976.
[cited by applicant]
Bibiloni et al.,“VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis.” Am J Gastroenterol., 100 (7): 1539-1546, 2005.
[cited by applicant]
Boltin et al., Mucin Function in Inflammatory Bowel Disease An Update. J. Clin. Gastroenterol., 47 (2): 106-111, 2003.
[cited by applicant]
Bork, “Powers and pitfalls in sequence analysis: The 70% hurdle,” Genome Research, 2000, 10:398-400.
[cited by applicant]
Botoman et al., “Management of Inflammatory Bowel Disease.” Am Fam Physician 57 (1): 57-68, 1998.
[cited by applicant]
Bowie et al., “Deciphering the message in protein sequences: tolerance to amino acid substitutions”, Science 247: 1306-1310, 1990.
[cited by applicant]
Bratt et al., “A phase 1 trial with transgenic bacteria expressing interleukin-IO in Crohn's disease.” Clinical Gastroenterology and Hepatology 4: 754-759, 2006.
[cited by applicant]
Burgess et al., “Possible Dissociation of the Heparin-binding and Mitogenic Activities of heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single…
[cited by applicant]
Cani et al., “Changes in Gut Micro biota Control Metabolic Endotoxemia-induced Inflammation in High-Fat Diet-Induced Obesity and Diabetes in Mice.” Diabetes 57: 1470-1481, 2008.
[cited by applicant]
Chassaign et al., “Dextran sulfate Sodium(DSS)-Induced Colitis in Mice” Curr Protoc Imunol, Feb. 2014,104: Unit-15.25.
[cited by applicant]
Chelakkot et al., “Mechanisms regulating intestinal barrier integrity and its pathological implications,” Experimental and Molecular Medicine, 2018, 50:103.
[cited by applicant]
Clevelandclinic.org, “Gastrointestinal Disorders” retrieved on Mar. 27, 2020, retrieved from https://my.clevelandclinic.org/health/articles/7040-gastrointestinal-disorders, 16 pages.
[cited by applicant]
Coskun et al., “Intestinal Epithelium in Inflammatory Bowel Disease.” Frontiers in Medicine 1: 24, 2014.
[cited by applicant]
Danese et al., “Etiopathogenesis of inflammatory bowel diseases.” World J. Gastroenterol., 12: 4807-4812, 2006.
[cited by applicant]
Daperno et al., “Results of the 2nd part Scientific Workshop of the ECCO. II: Measures and markers of prediction to achieve, detect, and monitor intestinal healing in inflammatory bowel disease.”, J Crohns Colitis., Oct…
[cited by applicant]
Delzenne et al., “Targeting gut microbiota in obesity: effects of prebiotics and probiotics.” Nature Reviews, 7 (11): 639-646, 2011.
[cited by applicant]
Deutscher, “Maintaining protein stability,” Methods in Enzymology, 1990, 182:83-89.
[cited by applicant]
Dewi et al., “In vitro assessment of human endothelial cell permeability: effects of inflammatory cytokines and dengue virus infection.” J Virol Methods., 121 (2): 171-180, 2004.
[cited by applicant]
Dewi et al., “Peripheral blood mononuclear cells increase the permeability of dengue virus-infected endothelial cells in association with down-regulation of vascular endothelial cadherin”, J. Gen. Virol. 89: 642-652, 20…
[cited by applicant]
Duncan et al., “Proposal of
[cited by applicant]
Durrer et al., “Genetically engineered probiotic for the treatment of phenylketonuria (PKU); assessment of a novel treatment in vitro and in the PAHenu2 mouse model of PKU.” PLoS One., 12(5): e0176286, 17 pages, 2017.
[cited by applicant]
EP European Extended Search Report in Appl. No. 19782209.1, dated May 4, 2021, 8 pages.
[cited by applicant]
EP European Extended Supplemental Search Report in International Appln. A48No. 18781398.5, dated Dec. 22, 2020, 9 pages.
[cited by applicant]
Everard et al., “Cross-talk between
[cited by applicant]
Everard et al., “Responses of Gut Micro biota and Glucose and Lipid Metabolism to Prebiotics in Genetic Obese and Diet-Induced Leptin-Resistant Mice.” Diabetes, 60 (11): 2775-2786, 2011.
[cited by applicant]
Frottin et al., “The Proteomics of N-terminal Methionine Cleavage,” Molecular & Cellular Proteomics 5.12, pp. 2336-2349, 2006.
[cited by applicant]
Gassler et al., “Inflammatory bowel disease is associated with changes of enterocytic junctions.” Am J. Physiol. Gastrointest. Liver Physiol., 28 (1): G216-G228, 2001.
[cited by applicant]
Gaston et al., “S-nitrosylation signaling in cell biology.”, Mol Interv. 3, 253-263, 2003.
[cited by applicant]
GenBank Accession No. AEN96375, hypothetical protein RHOM_06280[
[cited by applicant]
GenBank Accession No. AJ270482, “
[cited by applicant]
GenBank Accession No. CP003040, “
[cited by applicant]
Glozak et al., “Acetylation and deacetylation of non-histone proteins.”, Gene. 363, 15-23, 2005.
[cited by applicant]
Han et al., “Detergent-free biotin switch combined with liquid chromatography/tandem mass spectrometry in the analysis of S-nitrosylated proteins.”, Rapid Commun Mass Spectrom. 22, 1137-1145, 2008.
[cited by applicant]
Hanniffy et al., “Mucosal delivery of a pneumococcal vaccine using
[cited by applicant]
Harvey et al., “A Simple Index of Crohns-Disease Activity”, Lancet 1(8178): 1134-1135, 1980.
[cited by applicant]
Harvey et al., “Measuring Crohn's disease activity,” May 1980, The Lancet, 8178:1134-1135.
[cited by applicant]
Healthline.com, “Liver Diseases,” retrieved on accessed Mar. 27, 2020, pp. 1-14, retrieved from https://www.healthline.com/health/liver-diseases, 14 pages.
[cited by applicant]
Henikoff et al., “Amino acid substitution matrices from protein blocks”, Proc. Natl. Acad. Sci. 89(22): 10915-10919, 1992.
[cited by applicant]
Higgins et al., “CLUSTAL: a package for performing multiple sequence alignment on a microcomputer”, Gene 73: 237-244, 1988.
[cited by applicant]
Horhota et al., “Glycerol nucleoside triphosphates: Synthesis and polymerase substrate activities”, Organic Letters 8: 5345-5347, 2006.
[cited by applicant]
Hsiao et al., “High-frequency transformation of yeast by plasmids containing the cloned yeast ARG4 gene”, Proc. Natl. Acad. Sci. (USA), 76: 3829, 1979.
[cited by applicant]
Huynh et al., “Probiotic preparation VSL#3 induces remission in children with mild to moderate acute ulcerative colitis: a pilot study.” Inflamm Bowel Dis., 15 (5): 760-768, 2009.
[cited by applicant]
Imai et al., “Transcriptional silencing and longevity protein SIR2 is an NADdependent histone deacetylase.”, Nature. 403, 795-800, 2000.
[cited by applicant]
Inouye et al. Cloning and Sequence analysis of cDNA for the luminescent protein aequorin. Proceedings of the National Academy of Sciences, May 1985, 82(10):3154-3158.
[cited by applicant]
International Human Genome Sequencing Consortium, “Finishing the euchromatic sequence of the human genome,” Nature., 2004, 431:931-45.
[cited by applicant]
Irvine et al., “Quality of Life: A Valid and Reliable Measure of Therapeutic Efficacy in the Treatment of Inflammatory Bowel Disease”, Gastroenterology 106: 287-296, 1994.
[cited by applicant]
IUPAC Commission on the Nomenclature of Organic Chemistry (CNOC) and IUPAC-IUB Commission on Biochemical Nomenclature (CBN), Nomenclature of a Amino Acids, (Recommendations 1974), Biochemistry 14: 449-462, 1975.
[cited by applicant]
Jaffrey et al., “The Biotin Switch Method for the Detection of S-Nitrosylated Proteins.”, Sci. STKE. 2001.
[cited by applicant]
Jensen, “Modification-specific proteomics: Characterization of posttranslational modifications by mass spectrometry.”, Curr Opin Chem Biol. 8, 33-41, 2004.
[cited by applicant]
Johansson et al., “Bacteria penetrate the normally impenetrable inner colon mucus layer in both murine colitis models and patients with ulcerative colitis.” Gut., 63 (2): 281-291, 2014.
[cited by applicant]
Karlin et al., “Applications and statistics for multiple high-scoring segments in molecular sequences”, Proc. Natl. Acad. Sci. 90: 5873-5877, 1993.
[cited by applicant]
Keown et al., “Methods for Introducing DNA into mammalian cells,” Methods in Enzymology, 1990, 185:527-537.
[cited by applicant]
Kiesler et al., “Experimental Models of Inflammatory Bowel Diseases.”, Cell Mol Gastroenterol Hepatol, vol. 1, No. 2, pp. 154-170, 2015.
[cited by applicant]
Kim et al., “Investigating Intestinal Inflammation in DSS-induced Model of IBD.” Journal of Visualized Experiments, 60: pii: 3678, 171-180, 2012.
[cited by applicant]
Kyte and Doolittle, “A Simple Method for Displaying the Hydropathic Character of a Protein”, J Mol. Biol. 157: 105-132, 1982.
[cited by applicant]
Lazar et al., “Transforming Growth Factor a: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities,” Mol. Cell. Biol., 1988, 8:1247-1252.
[cited by applicant]
Lerner et al., “Dysbiosis may trigger autoimmune diseases via inappropriate posttranslational modification of host proteins.” Frontiers in Microbiology, vol. 7, Article 84, 2016.
[cited by applicant]
Levesque et al., “Converging goals of treatment of inflammatory bowel disease from clinical trials and practice.” Gastroenterology, 148 (1): 37-51.e1, 2015.
[cited by applicant]
Ma, “Animal models of disease,” Modern Drug Discovery, 2004, 7:6.
[cited by applicant]
Machiels et al., “A decrease of the butyrate-producing species
[cited by applicant]
Maloy et al., “Intestinal homeostasis and its breakdown in inflammatory bowel disease.”, Nature 474 (7351): 298-306, 2011.
[cited by applicant]
Mandic et al., “Evaluation of head and neck squamous cell carcinoma invasiveness by the electrical resistance breakdown assay.” Clin Exp Metastasis, 21 (8): 699-704, 2004.
[cited by applicant]
Mansour et al., “Disruption of the proto-oncogene int-2 in mouse embryo-derived stem cells: a general strategy for targeting mutations to non-selectable genes.”, Nature, 336: 348-352, 1988.
[cited by applicant]
Markus et al., “Cytokines in Inflammatory Bowel Disease.” Nature Reviews Immunology, 14 (5): 329-342, 2014.
[cited by applicant]
Martini et al., “Mend Your Fences: The Epithelial Barrier and Its Relationship With Mucosal Immunity in Inflammatory Bowel Disease.” Cellular and Molecular Gastroenterology and Hepatology 4 (1): 33-46, 2017.
[cited by applicant]
Matts, “The value of rectal biopsy in the diagnosis of ulcerative colitis.”, QJM, 30: 393-407, 1961.
[cited by applicant]
Mayo Clinic, “Metabolic syndrome,” retrieved on accessed Mar. 27, 2020, retrieved from https ://www. mayoclinic .org/diseases-conditions/metabolic-syndrome/diagnosis-treatment/drc-20351921, 5 pages.
[cited by applicant]
McCormick et al., “Mucin depletion in inflammatory bowel disease,” Journal of Clinical Pathology, 43: 143-146, 1990.
[cited by applicant]
MedlinePlus, “Neurologic Diseases,” retrieved on accessed Mar. 27, 2020, retrieved from https://medlineplus.gov/neurologicdiseases.html, 8 pages.
[cited by applicant]
[cited by applicant]
Merrifield. J., “Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide,” Am Chem Soc., 85: 2149-2154, 1963.
[cited by applicant]
Moayyedi et al., “Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial.” Gastroenterology 149 (1): 102-109.e6, 2015.
[cited by applicant]
Molodecky et al., “Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review.” Gastroenterology 142 (1): 46-54.e42, 2012.
[cited by applicant]
Myers et al., “Optimal alignments in linear space”, CABIOS 4: 11-17, 1988.
[cited by applicant]
Narula et al., “Fecal Microbiota Transplantation for Treatment of Active Ulcerative Colitis.” Inflamm Bowel Dis., 23 (10): 1702-1709, 2017.
[cited by applicant]
NCBI Protein Blast for SEQ ID No. 19,downloaded from https://blast.ncbi.nlm.nih.gov/Blast.cgi#alnHdr_ 1473652184 on Oct. 28, 2018, 9 pages.
[cited by applicant]
NCBI reference for WP _014079420.1 (downloaded from https://www.ncbi.nlm.nih.gov/protein/WP 014079420.1?report-genbank&log$=protalign&blast_rank=1&RID=XCKE8H21015; Published May 18, 2013,1 page.
[cited by applicant]
Needleman et al., “A general method applicable to the search for similarities in the amino acid sequence of two proteins”, J. Mol. Biol., 48(3): 444-453, 1970.
[cited by applicant]
Nuerath, “Cytokines in Inflammatory Bowel Disease.” Nature Reviews Immunology 14 (5): 329-342, 2014.
[cited by applicant]
Odenwald et al., “The intestinal epithelial barrier: A therapeutic target?” Nat. Rev. Gastroenterol Hepatol., Jan. 2017, 14:1:9-21.
[cited by applicant]
Paine, “Colonoscopic evaluation in ulcerative colitis.”, Gastroenterol Rep 2: 161-168, 2014.
[cited by applicant]
Pan et al., “Oral administration of
[cited by applicant]
Patterson et al., “Human Gut Symbiont
[cited by applicant]
PCT International Preliminary Report on Patentability in International Appln. No. PCT/US2019/026412, dated Oct. 6, 2020, 5 pages.
[cited by applicant]
PCT International Search Report and Written Opinion in International Appln No. PCT/US 2019/026412, dated Aug. 20, 2019, 10 pages.
[cited by applicant]
PCT International Search Report and Written Opinion, mailed Aug. 23, 2018, for International Application No. PCT/US2018/026447, 17 pages.
[cited by applicant]
Pearson et al., “Improved tools for biological sequence comparison”, Proc. Natl. Acad. Sci. 85: 2444-2448, 1988.
[cited by applicant]
Plovier et al., “A purified membrane protein from
[cited by applicant]
Qazi et al., “The risk of inflammatory bowel disease flares after fecal microbiota transplantation: Systematic review and meta-analysis.” Gut Microbes., 8 (6): 574-588, 2017.
[cited by applicant]
Sands et al., “Infliximab Maintenance Therapy for Fistulizing Crohn's Disease”, N Engl J Med 350 (9): 876-885, 2004.
[cited by applicant]
Sands, “From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation.” Gastroenterology 126 (6): 1518-1532, 2004.
[cited by applicant]
Sanger et al., “Challenges and prospects for pharmacotherapy in functional gastrointestinal disorders,” Therap Adv. Gastroenterol, Sep. 2010, 3:5:291-305.
[cited by applicant]
Schroeder et al., “Coated Oral 5-Aminosalicyclic Acid Therapy for Mildly to Moderate Active Ulcerative Colitis,” N Eng J Med, 317: 1625-1629, 1987.
[cited by applicant]
Shawki et al. “Mechanisms of Intestinal Epithelial Barrier Dysfunction by Adherent-Invasive
[cited by applicant]
Sheth et al., “Manipulating bacterial communities by in situ microbiome engineering.” Trends in Genetics 32 (4): 189-200, 2016.
[cited by applicant]
Shigemori et al., “Oral delivery of
[cited by applicant]
Simmonds et al., “Paneth cell metaplasia in newly diagnosed inflammatory bowel disease in children.” BMC Gastroenterol., 14: 93, 2014.
[cited by applicant]
Srinivasan et al., “TEER measurement techniques for in vitro barrier model systems.” J Lab Autom., 20 (2): 107-126, 2015.
[cited by applicant]
Srutkova et al., “
[cited by applicant]
Steidler et al., “Treatment of murine colitis by
[cited by applicant]
Strober et al., “Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases.” Gastroenterology, 140 (6): 1756-1767, 2011.
[cited by applicant]
Sturm et al., “Epithelial restitution and wound healing in inflammatory bowel disease,” World J Gastroenterol, 14(3): 348-353, 2008.
[cited by applicant]
Sutherland et al., “5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctitis, and Proctitis,” Gastroenterology, Jun. 1987, 92:6:1894-1898.
[cited by applicant]
ThermoFisher: www.thermofisher.com/US/en/home/lifo-science/cloning/genesynthesis/geneart-gene-synthesis/geneoptimizerhtm, “Invitrogen GeneArt Gene Synthesis”, 4 pages, 2017.
[cited by applicant]
Thia et al., “Measurement of Disease Activity in Ulcerative Colitis: Interobserver Agreement and Predictors of Severity”, Inflamm Bowel Dis, 17: 1757-1764, 2011.
[cited by applicant]
Tilg et al.,
[cited by applicant]
Travis et al., “Complete Genome Sequence of the Human Gut Symbiont
[cited by applicant]
Travis et al., “Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)”, Gut, 61: 535-542, 2012.
[cited by applicant]
Ulcerative Colitis: Introduction Johns Hopkins Medicine, found at: www.hopkinsmedicine.org/gastroenterology hepatology / pdfs/small large intestine/ulcerative_ colitis. pdf., 14 pages, 2013.
[cited by applicant]
UniProtKB—G2T1 E5 (G2T1 E5_ROSHA),“Uncharacterized protein—
[cited by applicant]
Van Solingen et al., “Fusion of Yeast Spheroplasts”, J. Bact, 130: 946-947, 1977.
[cited by applicant]
Van Solingen et al., “Fusion of yeast spheroplasts,” J. Bact, May 1977, 130:2:946.
[cited by applicant]
Vandenbroucke et al., “Active delivery of trefoil factors by genetically modified
[cited by applicant]
World Health Organization (WHO) model prescribing information: Drugs used in Bacterial Infections, 2001; report series No. 895: 1-179, 2001.
[cited by applicant]
Yan et al., “Colon-specific delivery of a probiotic-derived soluble protein ameliorates intestinal inflammation in mice through an EGFR-dependent mechanism.” J Clin Invest., 121 (6): 2242-2253, 2011.
[cited by applicant]
Yang et al., “Lysine acetylation: Codified crosstalk with other posttranslational modifications.”, Mol Cell. 31, 449-461, 2008.
[cited by applicant]
Zhang et al., “Cytokines, Inflammation and Pain”, Int. Anesthesiol. Clin. 45(2): 27-37, 2007.
[cited by applicant]
Zhang et al., “Interactions between intestinal microbiota and host immune response in inflammatory bowel disease,” Frontiers in Immunology, Aug. 2017, 8:942:1-13.
[cited by applicant]
Zolotaresky et al., “A membrane-permeant peptide that inhibits MLC kinase restores barrier function in in vitro models of intestinal disease.” Gastroenterology 123 (1): 163-172, 2002.
[cited by applicant]
Walsh-Reitz et al., “AMP-18 protects barrier function of colonic epithelial cells: role of tight junction proteins,” American Journal of Physiology—Gastrointestinal and Liver Physiology, Jul. 2005, 289(1):G163-71.
[cited by applicant]